Resources from the same session
New Treatment options for EGFR-Mutant NSCLC
Presenter: D. Planchard, FR
Session: Session 4 – Hitting the Target in 2024
Resources:
Slides
Webcast
Therapeutic Options in Uncommon EGFR-Mutant or HER2-Mutant NSCLC
Presenter: A-M. Dingemans, NL
Session: Session 4 – Hitting the Target in 2024
Resources:
Slides
Webcast
Participants Clinical Case Discussion: Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer
Presenter: Emmanouela Iliadi Manou, CH
Session: Session 4 – Hitting the Target in 2024
Resources:
Slides
Webcast
Participants Clinical Case Discussion: EGFR Mut NSCLC - Oligo – MET Uncommon
Presenter: Sara Oresti, IT
Session: Session 4 – Hitting the Target in 2024
Resources:
Slides
Webcast